Also trades as: AGYTF (OTC) · $vol 0M
AGY.L LSE
Allergy Therapeutics plc
1W: +0.0%
1M: -9.5%
3M: -30.4%
YTD: -59.4%
1Y: -40.6%
3Y: +66.7%
5Y: -99.8%
£4.82 ($0.06)
+0.07 (+1.56%)
Weekly Expected Move ±8.3%
£4
£4
£5
£5
£6
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$55M
-0.3% ▼
5Y CAGR: -6.8%
Gross Profit
$25M
-15.5% ▼
5Y CAGR: -15.3%
Operating Income
-$30M
+16.3% ▲
Net Income
-$40M
+0.2% ▲
EPS (Diluted)
$-0.01
+21.5% ▲
EBITDA
-$29M
+4.3% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $84M | $73M | $60M | $55M | $55M |
| YoY Growth | +7.8% | -13.7% | -18.1% | -7.4% | -0.3% |
| Cost of Revenue | $23M | $24M | $27M | $25M | $30M |
| Gross Profit | $62M | $49M | $33M | $30M | $25M |
| Gross Margin | 73.3% | 67.3% | 54.9% | 53.9% | 45.7% |
| R&D Expenses | $13M | $16M | $20M | $23M | $15M |
| SG&A Expenses | $46M | $47M | $49M | $42M | $38M |
| Operating Expenses | $59M | $62M | $73M | $65M | $55M |
| Operating Income | $4M | -$13M | -$35M | -$35M | -$30M |
| Operating Margin | 4.8% | -17.9% | -58.5% | -63.9% | -53.6% |
| Interest Expense | $386K | $541K | $2M | $4M | $7M |
| Income Before Tax | $4M | -$13M | -$43M | -$39M | -$40M |
| Tax Expense | $771K | $1M | $1M | $1M | -$312K |
| Net Income | $3M | -$14M | -$43M | -$40M | -$40M |
| Net Margin | 3.4% | -18.9% | -72.3% | -72.9% | -72.9% |
| EPS (Diluted) | $0.00 | $-0.02 | $-0.06 | $-0.01 | $-0.01 |
| EBITDA | $8M | -$9M | -$36M | -$31M | -$29M |
| Shares Outstanding | 677M | 643M | 670M | 3.74B | 4.77B |